Eli Lilly stock rises premarket after China approves weight-loss pill orforglipron
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Eli Lilly shares gained 2.8% premarket Thursday after China's medicine regulator approved the company's weight-loss pill orforglipron. Our AI stock portfolio is beating the S&P 500 by 118%. Discover the stocks we're buying and the opportunities we're watching…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe China approval gives Lilly an advantage over Novo Nordisk in the world's second-largest pharmaceutical market.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Eli Lilly shares gained 2.8% premarket Thursday.
- 02China's medicine regulator approved the weight-loss pill orforglipron.
- 03Orforglipron will compete in China with once-weekly GLP-1 injections from Novo Nordisk, Pfizer and Innovent.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Eli Lilly and Company1,437.76 USDMarket closedtoday +0.38%Positive Novo Nordisk A/S41.09 USDMarket closedtoday +0.96%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets